Femoropopliteal

IN.PACT Global: Follow Up of Real-Life Patient in Femoropopliteal Territory

Drug coated balloons (DCB) emerged as an innovative treatment approximately 10 years ago. Since then, numerous randomized...

Should We Start Stenting with DES in Femoropopliteal Territory?

Percutaneous intervention of femoropopliteal lesions have been the standard strategy these past two decades. The development of...

IVUS in Femoropopliteal PCI: Should We Start Using It?

For approximately two decades now, PCI has been the treatment of choice in femoropopliteal territory, and even...

Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Three randomized studies showed exercising significantly improves 6-minute walk outcomes in patients with peripheral artery disease (PAD)....

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite...

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between...

SOLACI PERIPHERAL | 6th Clinical Case: Common, Superficial and Deep Femoral Artery Recanalization

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Ana Paula Mollón (Arg.) presents “Common, Superficial...

Optimal Medical Treatment Under-used in Vascular Peripheral Disease

Less than half of patients undergoing endovascular revascularization for peripheral artery disease to their lower limbs are...